Diriger la réponse au VIH

This community guide was developed in response to the World Health Organisation Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

A community guide to the WHO 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infections

Scientific developments and the scale up of effective programmes have meant that AIDS-related deaths and new HIV infection rates are falling. Despite this, 2.3 million people became newly infected with HIV in 2012 – substantially more than the increase in the number of people on treatment in the same year.

The epidemic will continue to outpace the response unless the world accelerates the scale up of lifesaving HIV treatment and prevention. Over the years, it is people living with HIV and communities at the heart of the epidemic who have raised their voices for better research, advocated for cheaper, more effective and safer antiretroviral (ARV) drugs, delivered services to the most marginalised, and campaigned relentlessly to end preventable HIV infections and deaths.

Although there is no vaccine or cure as yet, a research breakthrough confirming that antiretroviral therapy (ART) can effectively prevent HIV transmission has given a new impetus to the HIV response. It is in this context that the World Health Organization (WHO) issued the new Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection in June 2013; a significant new contribution to efforts to make universal access to high-quality services a reality.

This Community guide was developed in response to the World Health Organization (WHO) 2013 Consolidated guidelines. It aims to assist community leaders and civil society organisations to:

• better understand the new WHO recommendations and guide country-level discussions on priorities (within civil society and between civil society and government)
• ensure the meaningful participation of communities most affected by HIV in national decision-making and planning
• advocate for any changes or further research necessary to adapt recommendations to suit their country context
• mobilise and prepare communities for the implementation of new recommendations

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.